Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

gefitinib

  • You have access
    Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status
    YUSUKE OKUMA, YUKIO HOSOMI, MAKOTO NAGAMATA, YUKO YAMADA, KUNIKO SEKIHARA, KAN KATO, TSUNEKAZU HISHIMA and TATSURU OKAMURA
    Anticancer Research November 2013, 33 (11) 5057-5064;
  • You have access
    Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations
    NOBUYUKI KOYAMA and YOSHITAKA UCHIDA
    Anticancer Research November 2013, 33 (11) 5083-5089;
  • You have access
    Comparison of the Time-to-response Between Radiotherapy and Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors for Advanced Non-small Cell Lung Cancer with EGFR Mutation
    HISAO IMAI, TAKEHITO SHUKUYA, TOSHIAKI TAKAHASHI, SAKAE FUJIWARA, KEITA MORI, AKIRA ONO, HIROAKI AKAMATSU, TETSUHIKO TAIRA, HIROTSUGU KENMOTSU, TATEAKI NAITO, KYOICHI KAIRA, HARUYASU MURAKAMI, HIDEYUKI HARADA, MASAHIRO ENDO, TAKASHI NAKAJIMA and NOBUYUKI YAMAMOTO
    Anticancer Research August 2013, 33 (8) 3279-3284;
  • You have access
    Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells
    MITSUHIRO SUENAGA, MASATATSU YAMAMOTO, SHO TABATA, SUSUMU ITAKURA, MASAAKI MIYATA, SHUICHI HAMASAKI and TATSUHIKO FURUKAWA
    Anticancer Research April 2013, 33 (4) 1547-1554;
  • You have access
    Gefitinib and Gemcitabine Coordinately Inhibited the Proliferation of Cholangiocarcinoma Cells
    YOSHIMI NAKAJIMA, HITOSHI TAKAGI, SATORU KAKIZAKI, NORIO HORIGUCHI, KEN SATO, NORIAKI SUNAGA and MASATOMO MORI
    Anticancer Research December 2012, 32 (12) 5251-5262;
  • You have access
    Effects of Voltage-gated K+ Channel Blockers in Gefitinib-resistant H460 Non-small Cell Lung Cancer Cells
    WON IL JEON, PAN DONG RYU and SO YEONG LEE
    Anticancer Research December 2012, 32 (12) 5279-5284;
  • You have access
    Interaction of Radiation and Gefitinib on a Human Lung Cancer Cell Line with Mutant EGFR Gene In Vitro
    YUMI SATO, TAKESHI EBARA, NORIAKI SUNAGA, TAKEO TAKAHASHI and TAKASHI NAKANO
    Anticancer Research November 2012, 32 (11) 4877-4881;

Pages

  • Previous
  • 1
  • 2
  • 3
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire